Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales

With Roche facing a fast decline for its oncology blockbuster trio amid a biosimilar onslaught, the drug giant is looking anywhere it can for a pick-me-up. That boost could come from Covid-19 diagnostics, the drugmaker said in a first-quarter update — but will it be enough?